17 November 2026
ONDINE BIOMEDICAL INC.
(“Ondine Biomedical”, “Ondine”, or “the Company”)
Journal of Hospital Infection Publishes Study Linking Steriwave® Implementation to 52.8% Relative Reduction in Conduit Harvest Site Infections
Interrupted time series of 2,172 CABG procedures reports nasal decolonisation compliance rising from 35.4% to 93.3% and conduit harvest surgical site infections falling from 3.6% to 1.7%.
Ondine Biomedical Inc. (AIM: OBI), a leader in light-activated antimicrobial therapies to prevent hospital infections, announces the publication of an independent, peer-reviewed clinical investigation in the Journal of Hospital Infection (“JHI”) conducted by researchers and clinicians at the University of Ottawa Heart Institute (“UOHI”).[1]
Following preliminary presentations at the Canadian Cardiovascular Congress (“CCC 2026”), the peer-reviewed publication provides complete 32-month interrupted time series data across 2,172 consecutive coronary artery bypass graft (“CABG”) procedures. The findings report that transitioning from multi-day outpatient administered topical antibiotic regimens to nurse-administered, point-of-care Steriwave® nasal photodisinfection was associated with 93.3% protocol adherence and a reduction in conduit harvest surgical site infections (“CHSSIs”) from 3.6% to 1.7%.
Key Publication Highlights
These results reflect a before-and-after comparison with mupirocin as used in routine practice at UOHI and are not a randomised comparison.
Dr. Fraser D. Rubens, MD, MSc, FRCSC, FACS, lead author, Professor of Cardiac Surgery at the University of Ottawa and Cardiac Surgeon at the University of Ottawa Heart Institute, stated:
"Surgical site infections following coronary bypass carry devastating physical and financial tolls. Our study found that moving away from complex, multi-day patient-administered antibiotic regimens to a nurse-delivered, point-of-care photodisinfection treatment substantially reduced the compliance barrier. Achieving 93.3% compliance across both elective and emergency cases was accompanied by a significant drop in harvest conduit wound infections, underscoring the operational value of universal point-of-care decolonisation."
Carolyn Cross, Chief Executive Officer of Ondine Biomedical, commented:
"We congratulate Dr. Rubens and the entire clinical research team at the University of Ottawa Heart Institute on this new publication in the Journal of Hospital Infection. Real-world clinical compliance is often the Achilles' heel of infection prevention, particularly in high-acuity cardiac surgery where urgent cases cannot accommodate a multi-day antibiotic-based decolonisation regimen.”
Enquiries:
|
Ondine Biomedical Inc. |
www.ondinebio.com |
|
Carolyn Cross, CEO |
+1 604 669 0555 |
|
|
|
|
Strand Hanson Limited (Nominated & Financial Adviser) |
|
|
James Harris, Richard Johnson, Imogen Ellis |
+44 (0)20 7409 3494 |
|
|
|
|
Peel Hunt LLP (Broker & Joint Financial Adviser) |
|
|
James Steel, Dr. Chris Golden |
+44 (0)20 7418 8900 |
|
|
|
|
5654 & Company (Financial PR and IR Adviser) |
ondinebiomedical@5654.co.uk |
|
Matthew Neal, Chris Gardner, Melissa Gardiner, Lucy Featherstone
|
+44 (0)791 7800 011 +44 (0)775 7697 357 +44 (0)7474 953 578
|
About the University of Ottawa Heart Institute
The University of Ottawa Heart Institute (UOHI) is Canada's largest cardiovascular health centre, serving as the primary tertiary and quaternary cardiac care hub for 14 regional hospital partners serving a population of nearly 2 million residents across Eastern Ontario. UOHI's primary geographic catchment covers approximately 18,000 square kilometres (7,000 square miles). Beyond its regional boundaries, UOHI accepts complex cardiac referrals from more than 40 hospitals across Western Quebec, Nunavut, and Newfoundland and Labrador. Renowned internationally for excellence in clinical care, research, and healthcare innovation, the Heart Institute manages over 270,000 patient visits and thousands of complex cardiac procedures annually, including open-heart surgeries, heart transplants, and mechanical circulatory support implantations. Supported by a workforce of over 1,500 healthcare professionals, researchers, and staff, UOHI houses Canada's premier cardiovascular research enterprise, seamlessly integrating bedside care with academic research to pioneer clinical standards and national quality initiatives. For more information, visit www.ottawaheart.ca.
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian life sciences company focused on the development of light-activated antimicrobial therapies ('photodisinfection') for the prevention and treatment of infections, including those associated with multidrug-resistant organisms. Ondine's lead photodisinfection product is authorised for nasal decolonisation in Canada, the UK and certain other international markets, where it is marketed as Steriwave®. The Company also has a pipeline of additional photodisinfection products in various stages of development for applications including chronic sinusitis, ventilator-associated pneumonia, burns and other indications.
About Steriwave® and its Mode of Action
Steriwave nasal photodisinfection is a light-activated antimicrobial therapy designed to rapidly eliminate potentially pathogenic microorganisms in the nose, a major reservoir from which pathogens can spread to cause infection. Applied by a healthcare professional, the treatment uses a proprietary photosensitising agent activated by red light to produce a rapid antimicrobial effect through oxidative mechanisms. Because the mechanisms act through non-antibiotic oxidative pathways, Steriwave has a low potential for the development of microbial resistance.
Regulatory Status and Clinical Data Disclaimer
Regulatory approvals, clearances and authorisations vary by jurisdiction, and indications, claims and availability may differ between markets. Ondine's photodisinfection products, including its nasal photodisinfection technology, are not approved or cleared by the U.S. Food and Drug Administration ("FDA") and are not commercially available in the United States, where they are limited by federal law to investigational use only. Their safety and effectiveness have not been established by the FDA, and any future U.S. marketing would be subject to FDA review and approval. No statement in this announcement should be interpreted as representing approval, clearance, authorisation or commercial availability in any jurisdiction, or for any use, where such status has not been granted.
References to clinical outcomes in this announcement should be interpreted in the context of the specific studies, real-world evaluations, endpoints and patient populations described, and do not imply regulatory approval for any particular indication or jurisdiction.
References